Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-6901
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update ; day:5 ; month:12 ; year:2017 ; pages:1-7
Drugs in R & D ; (5.12.2017), 1-7
- Schlagwort
-
Atemwegskrankheit
Atemnot
- Urheber
-
Rodríguez-Portal, José Antonio
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40268-017-0221-9
- URN
-
urn:nbn:de:1111-201802046961
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rodríguez-Portal, José Antonio
- SpringerLink (Online service)
Ähnliche Objekte (12)
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
Idiopathic pulmonary fibrosis
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study
Idiopathic pulmonary fibrosis
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis
Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis
Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients
Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium
A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK
Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study